ConductScience.org, home

Paper39441986

Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment.

Brettell SB and 16 others. J Med Chem, 2024. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment. Papers, record 39441986. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39441986

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment.
PubMed
Journal
J Med Chem
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
1.31, provisional
iCite
Revised in PubMed
2026-06-04
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brettell SBSkye Bhttps://orcid.org/0009-0003-4026-916X
2Janha OOmar
3Begen AAbbey
4Cann GGillian
5Sharma SSaumya
6Olaniyan NNiniola
7Yelland TTamas
8Hole AJAlison J
9Alam BBenazir
10Mayville EEmily
11Gillespie RRoss
12Capper MMichaelhttps://orcid.org/0000-0003-0102-6993
13Fidock DADavid A
14Milligan GGraemehttps://orcid.org/0000-0002-6946-3519
15Clarke DJDavid Jhttps://orcid.org/0000-0002-3741-2952
16Tobin ABAndrew Bhttps://orcid.org/0000-0002-1807-3123
17Jamieson AGAndrew Ghttps://orcid.org/0000-0003-1726-7353

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Plasmodium falciparumMajor topic
AntimalarialsMajor topic
Protein Kinase InhibitorsMajor topic
Humans
Protozoan Proteins
Hep G2 Cells
Structure-Activity Relationship
Protein Serine-Threonine Kinases
Malaria, Falciparum
Crystallography, X-Ray
Models, Molecular

Source PubMed

Download CSV of topics

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134355176Recent advances in the development of covalent inhibitors.RSC Med Chem2021https://conductscience.org/library/papers/34355176PubMed
228289248Antimalarial Drug Resistance: A Threat to Malaria Elimination.Cold Spring Harb Perspect Med2017https://conductscience.org/library/papers/28289248PubMed
328994500The Cysteinome of Protein Kinases as a Target in Drug Development.Angew Chem Int Ed Engl2018https://conductscience.org/library/papers/28994500PubMed
434921994Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.Pharmacol Res2022https://conductscience.org/library/papers/34921994PubMed
517521751Improved synchronous production of Plasmodium falciparum gametocytes in vitro.Mol Biochem Parasitol2007https://conductscience.org/library/papers/17521751PubMed
626272409Sexual development in Plasmodium parasites: knowing when it's time to commit.Nat Rev Microbiol2015https://conductscience.org/library/papers/26272409PubMed
737513939Covalent Inhibitors for Neglected Diseases: An Exploration of Novel Therapeutic Options.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37513939PubMed
829131621Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity.J Chem Inf Model2017https://conductscience.org/library/papers/29131621PubMed
925075834Spread of artemisinin resistance in Plasmodium falciparum malaria.N Engl J Med2014https://conductscience.org/library/papers/25075834PubMed
1021460447Data processing and analysis with the autoPROC toolbox.Acta Crystallogr D Biol Crystallogr2011https://conductscience.org/library/papers/21460447PubMed
1112929205The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum.PLoS Biol2003https://conductscience.org/library/papers/12929205PubMed
1211495584
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
J Med Chem2001https://conductscience.org/library/papers/11495584PubMed
1337652975Antimalarial drug discovery: progress and approaches.Nat Rev Drug Discov2023https://conductscience.org/library/papers/37652975PubMed
1433590753Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities.ACS Infect Dis2021https://conductscience.org/library/papers/33590753PubMed
1531170268Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.PLoS Pathog2019https://conductscience.org/library/papers/31170268PubMed
1631875044A Structurally-Validated Multiple Sequence Alignment of 497 Human Protein Kinase Domains.Sci Rep2019https://conductscience.org/library/papers/31875044PubMed
1722127061Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum.Nat Commun2011https://conductscience.org/library/papers/22127061PubMed
1830595467Plasmodium falciparum.Trends Parasitol2019https://conductscience.org/library/papers/30595467PubMed
19293115097-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors.Chem Pharm Bull (Tokyo)2018https://conductscience.org/library/papers/29311509PubMed
2031467193Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target.Science2019https://conductscience.org/library/papers/31467193PubMed

See all 36 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42900459Emerging antimalarial drug targets to combat drug-resistant malaria parasites.Infection2026https://conductscience.org/library/papers/42900459PubMed
42680902New thinking for the next generation of antimalarials.EMBO Mol Med2026https://conductscience.org/library/papers/42680902PubMed
42363832Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/42363832PubMed
42345078Using Unbiased Chemical Proteomics Approaches to Explore the Target Landscape of the Resistance Refractory 7-Azaindole MMV022224 in Plasmodium falciparum.ACS Infect Dis2026https://conductscience.org/library/papers/42345078PubMed
42127156Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression.PLoS Pathog2026https://conductscience.org/library/papers/42127156PubMed
41618901Shaping Antimalarials: A Geometry-First Approach to PfCLK3 Covalent Inhibitors.J Med Chem2026https://conductscience.org/library/papers/41618901PubMed
41131905Targeting Aurora Kinases as Essential Cell-Cycle Regulators to Deliver Multi-Stage Antimalarials Against Plasmodium Falciparum.Angew Chem Int Ed Engl2025https://conductscience.org/library/papers/41131905PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39441986

GET https://conductscience.org/api/papers/v1/39441986/references?page=2